Wegovy vs Zepbound: Which GLP-1 Is Better?

Bold opening Obesity is a chronic disease requiring long-term management, and GLP-1 receptor agonists like Wegovy and Zepbound have revolutionized treatment. Wegovy (semaglutide) was the first FDA-approved medication in this class for weight loss, while Zepbound (tirzepatide) offers a dual mechanism targeting both GLP-1 and GIP receptors. Both drugs promote significant weight loss, but differences in efficacy, side effects, cost, and insurance coverage make choosing between them complex. This evidence-based guide compares Wegovy and Zepbound to help patients and clinicians make informed decisions.

Wegovy vs Zepbound for Weight Loss

Clinical trials demonstrate that both Wegovy and Zepbound lead to substantial weight reduction, but Zepbound appears slightly more effective. In the STEP 1 trial, Wegovy (2.4 mg weekly) helped participants lose 14.9% of body weight over 68 weeks, compared to 2.4% with placebo. Meanwhile, the SURMOUNT-1 trial found that Zepbound (15 mg weekly) resulted in 20.9% weight loss over 72 weeks—nearly 6% more than Wegovy.

A key difference is the speed of weight loss. Zepbound users often see faster initial results due to its dual-action mechanism, while Wegovy’s effects accumulate more gradually. However, both drugs require lifestyle modifications (diet, exercise) for optimal outcomes. Patients with obesity-related comorbidities (e.g., type 2 diabetes, hypertension) may benefit from either, but Zepbound’s superior efficacy makes it a compelling choice for those needing greater weight reduction.

Side Effects Compared

Both Wegovy and Zepbound share common GLP-1-related side effects, primarily gastrointestinal (GI) issues. Wegovy’s most frequent adverse effects include nausea (44%), constipation (30%), and diarrhea (23%). These symptoms are usually mild-to-moderate and diminish over time. Rare but serious risks include pancreatitis, gallbladder disease, and potential thyroid tumors (as seen in rodent studies).

Zepbound’s side effect profile is similar but may be slightly more intense due to its additional GIP receptor activity. In trials, 50% of Zepbound users reported nausea, 20% experienced diarrhea, and 17% had constipation. Vomiting occurred in 12% of patients, compared to 9% with Wegovy. Both drugs carry warnings for pancreatitis and thyroid C-cell tumors, though human data remain limited.

For patients with a history of GI disorders (e.g., gastroparesis), Wegovy may be better tolerated due to its single-mechanism action. However, most side effects resolve within weeks, and gradual dose escalation minimizes discomfort.

Cost: Wegovy vs Zepbound

Cost is a major barrier to long-term use of both medications. Wegovy retails for $1,349 per month without insurance, while Zepbound costs $1,059 per month—a 21% difference. However, real-world expenses vary based on insurance coverage, copays, and manufacturer discounts.

Novo Nordisk offers a Wegovy savings card reducing out-of-pocket costs to $25/month for eligible patients (income-based). Eli Lilly provides a similar program for Zepbound, capping costs at $25/month for those with commercial insurance. Without coverage, Zepbound’s lower list price may make it more accessible, but Wegovy has been on the market longer, increasing the likelihood of insurance approval.

For Medicare/Medicaid beneficiaries, neither drug is covered for weight loss alone (only for diabetes under different brand names: Ozempic for Wegovy, Mounjaro for Zepbound). Patients should verify coverage before starting treatment, as cost disparities can influence adherence.

How They Work Differently

Wegovy and Zepbound both regulate appetite and glucose metabolism but through distinct mechanisms. Wegovy is a GLP-1 receptor agonist, mimicking the hormone glucagon-like peptide-1 to slow gastric emptying, reduce hunger, and increase satiety. It also improves insulin secretion and lowers blood sugar, making it beneficial for patients with prediabetes or type 2 diabetes.

Zepbound, however, is a dual GLP-1/GIP receptor agonist. GIP (glucose-dependent insulinotropic polypeptide) enhances insulin release and may further suppress appetite. Studies suggest GIP also promotes fat storage in adipose tissue, potentially improving body composition beyond weight loss alone. This dual action explains Zepbound’s superior efficacy in head-to-head comparisons.

Both drugs are administered via weekly subcutaneous injections, but Zepbound’s broader receptor targeting may offer metabolic advantages, particularly for patients with insulin resistance.

Which Is Better?

The “better” drug depends on individual patient factors. Wegovy is ideal for those who:

• Prefer a well-established medication with extensive long-term data.
• Have mild-to-moderate obesity (BMI 30–35) or obesity with comorbidities.
• Struggle with GI side effects (as Wegovy may be gentler).

Zepbound may be preferable for:

• Patients needing greater weight loss (e.g., BMI ≥35 or failed prior therapies).
• Those with type 2 diabetes, as its dual mechanism improves glycemic control.
• Individuals who tolerate GLP-1 side effects well and seek faster results.

For most patients, trial and error may be necessary. Clinicians should consider comorbidities, cost, and patient preferences when prescribing. Neither drug is a “magic bullet”—both require lifestyle changes for sustained success.

Switching Between Wegovy and Zepbound

Transitioning between Wegovy and Zepbound is possible but requires careful management. Patients switching from Wegovy to Zepbound should:

1. Complete the current Wegovy dose cycle before starting Zepbound.
2. Begin Zepbound at the lowest dose (2.5 mg) to minimize side effects, even if previously on a higher Wegovy dose.
3. Monitor for increased GI symptoms, as Zepbound’s dual mechanism may cause temporary discomfort.

Conversely, switching from Zepbound to Wegovy involves:

1. Stopping Zepbound and waiting 1–2 weeks before starting Wegovy to avoid overlapping effects.
2. Starting Wegovy at 0.25 mg and titrating up slowly.
3. Adjusting expectations, as Wegovy may result in slightly less weight loss than Zepbound.

Patients should consult their provider before switching, as dose adjustments and side effect management are critical for safety.

Insurance Coverage Compared

Insurance coverage for Wegovy and Zepbound varies widely. Wegovy has been FDA-approved for chronic weight management since 2021, making it more likely to be covered by commercial insurers (e.g., UnitedHealthcare, Aetna). However, many plans require prior authorization, proof of failed lifestyle interventions, or a BMI ≥30 (or ≥27 with comorbidities).

Zepbound, approved in 2023, faces stricter coverage criteria. Some insurers classify it as a “second-line” therapy, requiring patients to try Wegovy first. Medicare and Medicaid do not cover either drug for weight loss, though they may cover their diabetes counterparts (Ozempic, Mounjaro).

Patients should:

• Check their formulary for coverage details.
• Work with their doctor to submit prior authorization requests.
• Explore manufacturer savings programs if insurance denies coverage.

Frequently Asked Questions

Is Wegovy or Zepbound better?

Zepbound generally leads to greater weight loss (20.9% vs. 14.9% with Wegovy), but Wegovy has a longer safety record and may be better tolerated. The best choice depends on individual goals, side effect tolerance, and insurance coverage.

Can you switch from Wegovy to Zepbound?

Yes, but it requires dose adjustments and close monitoring for side effects. Patients should complete their current Wegovy dose cycle before starting Zepbound at the lowest dose (2.5 mg).

Which has fewer side effects?

Wegovy tends to cause milder GI side effects (nausea, constipation) compared to Zepbound, which has a higher incidence of nausea and vomiting due to its dual mechanism. However, most side effects resolve within weeks.

Disclaimer from Dr. Amanda Liu

The information provided is for educational purposes only and does not substitute for professional medical advice. Wegovy and Zepbound are prescription medications with risks and benefits that should be discussed with a healthcare provider. Individual results may vary, and long-term data on these drugs are still emerging. Always consult your physician before starting or switching medications.